VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | Optimizing CRC and uHCC outcomes with TKIs

Michel Ducreux, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses whether TKIs have the potential to optimize outcomes in refractory metastatic colorectal cancer (mCRC) and unresectable hepatocellular carcinoma (uHCC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter